Breaking News Instant updates and real-time market news.

FB

Facebook

$172.56

-12.53 (-6.77%)

09:32
03/20/18
03/20
09:32
03/20/18
09:32

Credit Suisse remains a buyer of Facebook

After media outlets reported data was harvested from Facebook through the use of an app where users were paid to take a personality test and agreed to have their data collected for "academic use," Credit Suisse analyst Stephen Ju notes that Facebook has already outlined its plans during Q3 earnings call to double headcount addressing user security, so he does not anticipate material change to OpEx guidance. The analyst believes the stock will be subject to further headline risk in the coming weeks as senior management is summoned to DC for hearings with lawmakers, but he remains a buyer. Ju reiterates an Outperform rating and $240 price target on the shares.

  • 22

    Mar

  • 11

    Apr

FB Facebook
$172.56

-12.53 (-6.77%)

03/20/18
MSCO
03/20/18
NO CHANGE
Target $230
MSCO
Overweight
Morgan Stanley answers 'top 4 investor questions' about Facebook
Morgan Stanley analyst Brian Nowak identified the top four questions he's heard from Facebook investors and outlined his answers in a new note. Addressing "What should Facebook do?", Nowak's take is that the company should become more assertive about the mistakes it has made and how it intends to fix them. On the question of "regulatory risk," he does believe the Cambridge Analytica news has increased Facebook's risk, which he contends only furthers the impetus to begin to take control of the public message, self-regulate and improve safeguards. On the question of "fundamental risk," Nowak said he does not see a fundamental risk to revenue or EPS as of now and he is not changing his FY18 and FY19 forecasts, though he adds that the "drumbeat of negative news and headlines" increases the risk that there is some user backlash and an "eventual" advertiser backlash. On the question of whether Facebook's multiple has bottomed, Nowak said "Yes, but this isn't new," as he noted that its multiple makes the stock cheaper than Alphabet (GOOGL), eBay (EBAY) and "many other assets" that are growing more slowly and/or don't have as much long-term monetization potential. Nowak maintains his Overweight rating and $230 price target on Facebook shares.
03/20/18
DBAB
03/20/18
NO CHANGE
DBAB
Buy
Facebook valuation 'extremely compelling' despite risks, says Deutsche Bank
Deutsche Bank analyst Lloyd Walmsley sees three key risks for Facebook surrounding the Cambridge Analytica issue: ongoing headline risk that perpetuates a negative news cycle, direct risk around Facebook's perceived data security, and potential indirect impact from data regulations/legislation that ultimately curbs the company's ability to serve hyper targeted ads. The analyst, however, takes comfort in Facebook's "improving handling of other recent issues and its best-in-class overall execution." He sees a "large distance" between the current issues and any legislation that would curb Facebook's ad targeting in a meaningful way. As such, Facebook's valuation is "extremely compelling despite the increased risks," Walmsley tells investors in a research note.
03/20/18
COWN
03/20/18
NO CHANGE
Target $220
COWN
Outperform
Facebook shares likely to remain under pressure, says Cowen
Cowen analyst John Blackledge said shares of Facebook are likely to remain under pressure as the story around the improper use of user data develops. In a research note to investors, Blackledge noted that Facebook ad executive Carolyn Everson addressed the press reports at Shoptalk, adding that Everson "reassured those in attendance, which includes both users and advertising partners, that its users privacy is of the upmost importance." According to Everson, Facebook believed that all the improperly obtained data was deleted, but "recently were made aware that this may not be the case." Blackledge has an Outperform rating and $220 price target on Facebook shares.
03/20/18
BOFA
03/20/18
NO CHANGE
Target $265
BOFA
Buy
Facebook is 'oversold' with 'limited' near term catalysts, says BofA/Merrill
BofA/Merrill analyst Justin Post is keeping his Buy rating and $265 price target on Facebook, writing that while the stock is oversold, the compounding news flow raising privacy concerns is adding to risk. Post says that sentiment could remain pressured with looming General Data Protection Regulation enforcement coming into force in late Q2, adding that the company could use some added visibility on any impact in terms of user engagement and financial conditions. Longer term, the analyst believes that the current valuation makes the stock "compelling".

TODAY'S FREE FLY STORIES

TSLA

Tesla

$298.32

-0.63 (-0.21%)

18:44
09/20/18
09/20
18:44
09/20/18
18:44
Periodicals
Tesla VP of global supply management O'Connor to leave company, Bloomberg says »

Liam O'Connor,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 26

    Sep

  • 29

    Oct

CRBP

Corbus Pharmaceuticals

$7.90

2.75 (53.40%)

18:34
09/20/18
09/20
18:34
09/20/18
18:34
Hot Stocks
Corbus CEO says wants to be leading pipeline for synthetic endocannabinoids »

Corbus Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 01

    Oct

MCD

McDonald's

$160.84

1.65 (1.04%)

18:32
09/20/18
09/20
18:32
09/20/18
18:32
Hot Stocks
McDonald's says dividend hike reinforces confidence in long-term targets »

McDonald's says the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

MCD

McDonald's

$160.84

1.65 (1.04%)

18:31
09/20/18
09/20
18:31
09/20/18
18:31
Hot Stocks
McDonald's raises quarterly dividendy by 15% to $1.16 per share »

McDonald's board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

TTPH

Tetraphase

$3.16

0.14 (4.64%)

18:10
09/20/18
09/20
18:10
09/20/18
18:10
Recommendations
Tetraphase analyst commentary  »

Tetraphase's XERAVA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

SGH

Smart Global

$30.44

0.7 (2.35%)

18:07
09/20/18
09/20
18:07
09/20/18
18:07
Syndicate
Breaking Syndicate news story on Smart Global »

Smart Global files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 04

    Oct

  • 10

    Oct

SGH

Smart Global

$30.44

0.7 (2.35%)

18:07
09/20/18
09/20
18:07
09/20/18
18:07
Syndicate
Breaking Syndicate news story on Smart Global »

Smart Global files $150M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 04

    Oct

  • 10

    Oct

PIR

Pier 1 Imports

$1.80

0.045 (2.56%)

17:46
09/20/18
09/20
17:46
09/20/18
17:46
Recommendations
Pier 1 Imports analyst commentary  »

Pier 1 Imports price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MU

Micron

$46.06

1.01 (2.24%)

17:43
09/20/18
09/20
17:43
09/20/18
17:43
Hot Stocks
Breaking Hot Stocks news story on Micron »

Micron reverses, now down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 20

    Sep

  • 24

    Sep

  • 25

    Sep

ACXM

Acxiom

$50.28

2.09 (4.34%)

, IPG

Interpublic Group

$22.68

0.315 (1.41%)

17:41
09/20/18
09/20
17:41
09/20/18
17:41
Hot Stocks
Acxiom shareholders approve AMS sale, will switch name to LiveRamp after close »

Acxiom (ACXM) announced…

ACXM

Acxiom

$50.28

2.09 (4.34%)

IPG

Interpublic Group

$22.68

0.315 (1.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

IPCI

Intellipharmaceutics

$2.92

0.15 (5.42%)

17:39
09/20/18
09/20
17:39
09/20/18
17:39
Syndicate
Breaking Syndicate news story on Intellipharmaceutics »

Intellipharmaceutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOC

Northrop Grumman

$301.53

-10.71 (-3.43%)

17:30
09/20/18
09/20
17:30
09/20/18
17:30
Hot Stocks
Northrop Grumman completes first qualification test of rocket motor in Atlas V »

Northrop Grumman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YUM

Yum! Brands

$88.96

0.39 (0.44%)

17:28
09/20/18
09/20
17:28
09/20/18
17:28
Recommendations
Yum! Brands analyst commentary  »

Yum! Brands continues to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

17:25
09/20/18
09/20
17:25
09/20/18
17:25
Conference/Events
SEC to hold an investor roundtable »

Investor Roundtable to…

FSCT

ForeScout

$39.56

1.2 (3.13%)

17:24
09/20/18
09/20
17:24
09/20/18
17:24
Hot Stocks
ForeScout beneficial owner Amadeus Capital Partners sells $4.6M in shares »

ForeScout beneficial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

MU

Micron

$46.06

1.01 (2.24%)

17:23
09/20/18
09/20
17:23
09/20/18
17:23
Hot Stocks
Micron says it is seeing CPU shortage »

Says confident of long…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 20

    Sep

  • 24

    Sep

  • 25

    Sep

CWK

Cushman & Wakefield

$18.00

0.37 (2.10%)

17:21
09/20/18
09/20
17:21
09/20/18
17:21
Hot Stocks
Cushman & Wakefield arranges $55M sale of a Whole Foods property »

A 50,451-square-foot…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACAD

Acadia

$19.08

3.97 (26.27%)

17:17
09/20/18
09/20
17:17
09/20/18
17:17
Hot Stocks
Acadia issues states affirming positive risk profile of NUPLAZID »

ACADIA Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

UNFI

United Natural Foods

$33.83

0.54 (1.62%)

17:16
09/20/18
09/20
17:16
09/20/18
17:16
Hot Stocks
United Natural Foods plunges after Q4 margins fall to 14.5% »

Shares of United Natural…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 28

    Oct

MDXG

MiMedx

$6.18

0.68 (12.36%)

17:15
09/20/18
09/20
17:15
09/20/18
17:15
Hot Stocks
MiMedx announces Nasdaq listing extension »

MiMedx Group announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Oct

MDXG

MiMedx

$6.18

0.68 (12.36%)

17:15
09/20/18
09/20
17:15
09/20/18
17:15
Hot Stocks
MiMedx: Previous executive separations to be treated as termination 'for cause' »

The Board of Directors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Oct

UTX

United Technologies

$141.91

1.41 (1.00%)

17:11
09/20/18
09/20
17:11
09/20/18
17:11
Hot Stocks
United Technologies awarded $2.46B Department of Defense contract modification »

United Technologies has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NEXA

Nexa Resources

$11.89

0.1 (0.85%)

17:10
09/20/18
09/20
17:10
09/20/18
17:10
Hot Stocks
Nexa Resources authorizes $30M share buyback program »

Nexa Resources has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AT

Atlantic Power

$2.15

-0.025 (-1.15%)

17:06
09/20/18
09/20
17:06
09/20/18
17:06
Hot Stocks
Atlantic Power to acquire two biomass plants in South Carolina for $13M »

Atlantic Power…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VNDA

Vanda Pharmaceuticals

$20.00

0.4 (2.04%)

17:05
09/20/18
09/20
17:05
09/20/18
17:05
Hot Stocks
Vanda Pharmaceuticals announces HETLIOZ patent listing in FDA Orange Book »

Vanda Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.